Realizing this vision means successfully developing new, safe and effective treatment options for patients suffering from Type 2 diabetes and other metabolic disorders. We aim in parallel to create substantial added value for our investors. We expect to achieve these aims by exploiting our development expertise and fully leveraging the benefits of our technology.